Perspective Therapeutics, Inc. (NYSE:CATX) Given Consensus Rating of “Buy” by Brokerages

Perspective Therapeutics, Inc. (NYSE:CATX) has earned a consensus rating of “Buy” from the eleven analysts that are currently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a hold recommendation, seven have given a buy recommendation and three have issued a strong buy recommendation on the company. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is $12.50.

CATX has been the topic of a number of research reports. Scotiabank began coverage on Perspective Therapeutics in a research note on Friday, March 7th. They issued a “sector outperform” rating and a $15.00 price objective on the stock. Cantor Fitzgerald upgraded shares of Perspective Therapeutics to a “strong-buy” rating in a research report on Tuesday, March 4th. Brookline Capital Management upgraded shares of Perspective Therapeutics to a “strong-buy” rating in a report on Monday, March 10th. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price target on shares of Perspective Therapeutics in a report on Monday, March 31st. Finally, Lifesci Capital raised Perspective Therapeutics to a “strong-buy” rating in a research note on Thursday, March 6th.

Perspective Therapeutics Stock Performance

Shares of Perspective Therapeutics stock opened at $2.39 on Friday. Perspective Therapeutics has a twelve month low of $1.60 and a twelve month high of $16.70. The business has a 50-day moving average price of $2.24 and a 200-day moving average price of $3.38.

Insider Transactions at Perspective Therapeutics

In related news, CFO Juan Graham acquired 33,333 shares of the firm’s stock in a transaction that occurred on Friday, March 28th. The stock was purchased at an average cost of $2.25 per share, for a total transaction of $74,999.25. Following the purchase, the chief financial officer now directly owns 35,354 shares of the company’s stock, valued at $79,546.50. This trade represents a 1,649.33% increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Robert F. Williamson III bought 38,145 shares of Perspective Therapeutics stock in a transaction on Monday, March 31st. The stock was purchased at an average price of $2.14 per share, with a total value of $81,630.30. Following the completion of the acquisition, the director now directly owns 108,982 shares of the company’s stock, valued at $233,221.48. This represents a 53.85% increase in their position. The disclosure for this purchase can be found here. In the last 90 days, insiders have bought 115,696 shares of company stock valued at $256,344. 3.72% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Perspective Therapeutics

Several hedge funds have recently modified their holdings of the stock. Y Intercept Hong Kong Ltd purchased a new stake in Perspective Therapeutics in the fourth quarter valued at approximately $33,000. Aigen Investment Management LP acquired a new position in Perspective Therapeutics during the fourth quarter valued at $34,000. National Bank of Canada FI raised its stake in shares of Perspective Therapeutics by 549,900.0% during the 4th quarter. National Bank of Canada FI now owns 11,000 shares of the company’s stock valued at $35,000 after buying an additional 10,998 shares during the last quarter. ProShare Advisors LLC raised its stake in shares of Perspective Therapeutics by 49.1% during the 4th quarter. ProShare Advisors LLC now owns 15,225 shares of the company’s stock valued at $49,000 after buying an additional 5,011 shares during the last quarter. Finally, Vontobel Holding Ltd. purchased a new stake in shares of Perspective Therapeutics in the fourth quarter worth about $51,000. Institutional investors and hedge funds own 54.66% of the company’s stock.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.